ArticleFrontiers in oncology2021

Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study.

Caiyun Nie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.